- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mallinckrodt receives clearance for OptiMark
Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.The
Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.
The segment of the MR market into which OptiMark will be sold is worth more than $150 million annually and is growing at a rate of 12% to 15%, according to the St. Louis-based vendor. Mallinckrodt already sells another MR contrast agent, GastroMark, for use in imaging of the gastrointestinal tract. The company expects to begin shipping OptiMark this quarter.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
